Analyst Price Targets — ACHV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 29, 2026 8:15 pm | — | Stifel Nicolaus | $18.00 | $7.69 | TheFly | Achieve Life Sciences initiated with a Buy at Stifel |
| August 13, 2026 6:43 am | Maxwell Skor | Morgan Stanley | $13.00 | $6.69 | StreetInsider | Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight |
| August 12, 2026 12:37 pm | Ryan Deschner | Raymond James | $18.00 | $6.66 | TheFly | Achieve Life Sciences price target lowered to $18 from $20 at Raymond James |
| August 12, 2026 11:27 am | Brandon Folkes | H.C. Wainwright | $12.00 | $6.77 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV) |
| June 26, 2026 12:11 pm | — | Raymond James | $20.00 | $5.91 | TheFly | Achieve Life Sciences resumed with a Strong Buy at Raymond James |
| April 20, 2026 8:20 pm | — | Canaccord Genuity | $13.00 | $4.25 | TheFly | Achieve Life Sciences initiated with a Buy at Canaccord |
| May 13, 2024 7:36 am | Francois Brisebois | Oppenheimer | $5.50 | $2.42 | StreetInsider | Achieve Life Sciences (ACHV) PT Lowered to $11 at Oppenheimer |
| November 16, 2022 9:01 am | — | Maxim Group | $4.00 | $1.13 | Benzinga | Maxim Group Maintains Buy on Achieve Life Sciences, Lowers Price Target to $8 |
Latest News for ACHV
SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications.…
SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares…
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $7.69, but opened at $8.08. Achieve Life Sciences shares last traded at $8.0310, with a volume of 186,199 shares traded. Analysts Set New Price Targets Several analysts have recently weighed
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACHV.
U.S. House Trading
No House trades found for ACHV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.